in vitro PHARMACOLOGY 2011 CATALOG - Cerep
in vitro PHARMACOLOGY 2011 CATALOG - Cerep
in vitro PHARMACOLOGY 2011 CATALOG - Cerep
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
27<br />
❚ cannab<strong>in</strong>oid<br />
CB 1 - agonist radioligand<br />
b<strong>in</strong>d<strong>in</strong>g<br />
Ref. 0036<br />
Q 3 weeks<br />
Included <strong>in</strong>:<br />
ExpresS Profile<br />
High-throughput profile<br />
Diversity profile<br />
BioPr<strong>in</strong>t ® profile<br />
Organ safety profile<br />
Source<br />
Ligand<br />
Kd<br />
Non specific<br />
Reference<br />
human recomb<strong>in</strong>ant (CHO cells)<br />
[ 3 H]CP 55940 (0.5 nM)<br />
3.5 nM<br />
WIN 55212-2 (10 µM)<br />
CP 55940 (IC 50 : 0.58 nM)<br />
specific b<strong>in</strong>d<strong>in</strong>g (% of control)<br />
100<br />
50<br />
0<br />
-11 - 10 -9 -8 -7 -6 -5<br />
CP 55940<br />
WIN 55212-2<br />
AM 281<br />
anandamide<br />
log [drug] (M)<br />
R<strong>in</strong>aldi-Carmona, M. et al. (1996) J. Pharmaco. Exp. Ther., 278: 871-878.<br />
[CUSTOM OFFER] at cerebellum model (Ref. 0035), please contact us at customresearch@cerep.com<br />
<strong>Cerep</strong><br />
services<br />
<br />
Receptors<br />
[GPCRs]<br />
Ion<br />
channels<br />
CB 1<br />
cellul ar<br />
Ref. 1744<br />
Ref. 1745<br />
Q 3 weeks<br />
Agonist effect<br />
Antagonist effect<br />
Source<br />
human recomb<strong>in</strong>ant (CHO cells)<br />
Measured product cAMP<br />
Detection method HTRF<br />
Agonist effect Control CP 55940 (100 nM)<br />
Reference CP 55940 (EC 50 : 0.8 nM)<br />
Antagonist effect Stimulant CP 55940 (10 nM)<br />
Reference AM 281 (IC 50 : 100 nM)<br />
Felder, C.C. et al. (1995) Mol. Pharmacol., 48: 443-450.<br />
cAMP modulation (% of control)<br />
100<br />
100<br />
50<br />
50<br />
0<br />
0<br />
-12 -11 -10 -9 -8 -7 -6 -5 -4 -12 -11 -10 -9 -8 -7 -6 -5<br />
log [agonist] (M)<br />
log [antagonist] (M)<br />
CP 55940<br />
AM 281<br />
WIN 55212-2<br />
AM 251<br />
anandamide<br />
AM 630<br />
JWH 133<br />
[Solvent] must be kept ≤ 0.3%<br />
Transporters<br />
K<strong>in</strong>ases<br />
CB 1 - <strong>in</strong>verse agonist effect<br />
cellul ar<br />
Ref. 2378<br />
Q 3 weeks<br />
Source<br />
Measured product cAMP<br />
Detection method HTRF<br />
human recomb<strong>in</strong>ant (CHO cells)<br />
Control<br />
AM 281 (3 µM)<br />
Reference AM 281 (EC 50 : 33.2 nM)<br />
[Solvent] must be kept ≤ 0.3%<br />
Ross, R.A. et al. (1999) Brit. J. Pharmacol., 126: 665-672.<br />
<br />
-12 -11<br />
-11 -10<br />
-12 -11<br />
<br />
-12 -11<br />
-9 -8 -7 -6 -5 -4<br />
-10 -9 -8 -7<br />
-10 -9 -8 -7<br />
-10 -9 -8 -7 -6 -5<br />
-9 -8 -7 -6 -5<br />
-10 -4<br />
<br />
-11 -10<br />
<br />
-9 -8 -7 -6 -5 -4<br />
<br />
<br />
<br />
<br />
Epigenetic &<br />
DNA-related<br />
enzymes<br />
Other<br />
enzymes<br />
CB 1<br />
tissue<br />
Ref. 0307<br />
Q 4 weeks<br />
Source<br />
mouse vas deferens (field-stimulated)<br />
Agonist CP 55940 (pD 2 = 8.7)<br />
Antagonist AM 281<br />
Test concentrations 3 concentrations, n=2 (2 tissues)<br />
for both activities<br />
[Solvent] must be kept ≤ 0.1%<br />
R<strong>in</strong>aldi-Carmona, M. et al. (1994) FEBS Lett., 350: 240-244.<br />
tension (% of control)<br />
100<br />
<br />
50<br />
<br />
<br />
0<br />
-9 -7 -6<br />
-10 -8<br />
log [agonist] (M) <br />
CP 55940<br />
anandamide<br />
Specialized<br />
cellular<br />
assays<br />
Standard<br />
profiles<br />
<br />
CB 2 - agonist radioligand<br />
b<strong>in</strong>d<strong>in</strong>g<br />
Ref. 0037<br />
Q 3 weeks<br />
Included <strong>in</strong>:<br />
Diversity profile<br />
BioPr<strong>in</strong>t ® profile<br />
Organ safety profile<br />
Source<br />
Ligand<br />
Kd<br />
Non specific<br />
Reference<br />
human recomb<strong>in</strong>ant (CHO cells)<br />
[ 3 H]WIN 55212-2 (0.8 nM)<br />
1.5 nM<br />
WIN 55212-2 (5 µM)<br />
WIN 55212-2 (IC 50 : 1 nM)<br />
Munro, S. et al. (1993) Nature, 365: 61-65.<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Test<strong>in</strong>g<br />
conditions<br />
Order<strong>in</strong>g<br />
<strong>in</strong>formation<br />
For further details and updated <strong>in</strong>formation on assays:<br />
❚ Please go to www.cerep.com catalog onl<strong>in</strong>e or contact us at sales@cerep.com<br />
❚ Europe: +33 (0)5 49 89 30 00 – USA: +1 (425) 895 8666 – Japan: +81 (0)3 3354 4026 – Ch<strong>in</strong>a: +86 21 5132 0568<br />
Assay developed <strong>in</strong> 2010 New assay conditions Human Q Standard turnaround time<br />
Assay list<br />
& <strong>in</strong>dex